Supporting data for "An Investigational Study Into the Drug-Associated Mutational signature in SARS-CoV-2 viruses"

This study set out to gain a better understanding of how approved drugs with mutagenic potential may incur mutational burden on SARS-CoV-2 during long-term infection and the effects on molecular evolution and comparative fitness in resulting SARS-CoV-2 viruses. A serial passage of SARS-CoV-2 in presence of various approved drugs that may be administered to immunocompromised COVID-19 patients for antiviral purposes or as a part of treatment for other common co-morbidities (neoplasms or HIV infection) was conducted to study the mutations accrued by drug-treated viral quasispecies. Next-generation sequencing studies were utilized to study the genomic variations of the viral quasispecies, and the comparative fitness of different viral populations obtained from the passage was evaluated on in vitro and in vivo models.